

Nicholas B La Thangue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8410816/publications.pdf>

Version: 2024-02-01

33
papers

3,326
citations

331259
21
h-index

395343
33
g-index

33
all docs

33
docs citations

33
times ranked

6970
citing authors

#	ARTICLE	IF	CITATIONS
1	Arginine methylation regulates the p53 response. <i>Nature Cell Biology</i> , 2008, 10, 1431-1439.	4.6	405
2	HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. <i>Immunology and Cell Biology</i> , 2012, 90, 85-94.	1.0	392
3	SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability. <i>Cell Reports</i> , 2014, 7, 2006-2018.	2.9	370
4	HDAC inhibitor-based therapies: Can we interpret the code?. <i>Molecular Oncology</i> , 2012, 6, 637-656.	2.1	271
5	Predictive biomarkers: a paradigm shift towards personalized cancer medicine. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 587-596.	12.5	259
6	Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. <i>Cancer Cell</i> , 2015, 28, 557-568.	7.7	244
7	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. <i>Cancer Research</i> , 2015, 75, 5106-5119.	0.4	193
8	Arginine methylation controls growth regulation by E2F-1. <i>EMBO Journal</i> , 2012, 31, 1785-1797.	3.5	178
9	Arginine Methylation-Dependent Reader-Writer Interplay Governs Growth Control by E2F-1. <i>Molecular Cell</i> , 2013, 52, 37-51.	4.5	119
10	DNA damage response control of E2F7 and E2F8. <i>EMBO Reports</i> , 2008, 9, 252-259.	2.0	112
11	Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. <i>Cell Chemical Biology</i> , 2017, 24, 371-380.	2.5	111
12	To live or let die – complexity within the E2F1 pathway. <i>Molecular and Cellular Oncology</i> , 2015, 2, e970480.	0.3	85
13	Actin nucleation by WH2 domains at the autophagosome. <i>Nature Communications</i> , 2015, 6, 7888.	5.8	79
14	Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses. <i>Scientific Reports</i> , 2016, 6, 26430.	1.6	76
15	Citrullination-acetylation interplay guides E2F-1 activity during the inflammatory response. <i>Science Advances</i> , 2016, 2, e1501257.	4.7	64
16	Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11341-11346.	3.3	39
17	Post-translational control of transcription factors: methylation ranks highly. <i>FEBS Journal</i> , 2015, 282, 4450-4465.	2.2	38
18	Deacetylation of Chromatin and Gene Expression Regulation: A New Target for Epigenetic Therapy. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 1-17.	0.2	38

#	ARTICLE	IF	CITATIONS
19	Actin nucleators in the nucleus: an emerging theme. <i>Journal of Cell Science</i> , 2012, 125, 3519-3527.	1.2	36
20	Regulation of actin nucleation and autophagosome formation. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 3249-3263.	2.4	35
21	CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation. <i>Cell Chemical Biology</i> , 2017, 24, 9-23.	2.5	32
22	TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism. <i>Cancer Research</i> , 2016, 76, 6975-6987.	0.4	21
23	PRMT5 promotes cancer cell migration and invasion through the E2F pathway. <i>Cell Death and Disease</i> , 2020, 11, 572.	2.7	20
24	Arginine methylation expands the regulatory mechanisms and extends the genomic landscape under E2F control. <i>Science Advances</i> , 2019, 5, eaaw4640.	4.7	19
25	Tudor-domain protein PHF20L1 reads lysine methylated retinoblastoma tumour suppressor protein. <i>Cell Death and Differentiation</i> , 2017, 24, 2139-2149.	5.0	18
26	Immune modulation underpins the anti-cancer activity of HDAC inhibitors. <i>Molecular Oncology</i> , 2021, 15, 3280-3298.	2.1	18
27	A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. <i>Cancer</i> , 2019, 125, 99-108.	2.0	17
28	HDAC Inhibitors. <i>Methods in Molecular Biology</i> , 2016, 1436, 281-303.	0.4	13
29	Linker Histone H1.2 Directs Genome-wide Chromatin Association of the Retinoblastoma Tumor Suppressor Protein and Facilitates Its Function. <i>Cell Reports</i> , 2017, 19, 2193-2201.	2.9	10
30	The TLR Adaptor Protein MyD88 Mediates Cell Sensitivity to HDAC Inhibitors through a Cytokine-Dependent Mechanism. <i>Blood</i> , 2016, 128, 1766-1766.	0.6	7
31	Functional interplay between E2F7 and ribosomal rRNA gene transcription regulates protein synthesis. <i>Cell Death and Disease</i> , 2018, 9, 577.	2.7	4
32	A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma. <i>BMC Cancer</i> , 2021, 21, 851.	1.1	2
33	Linking H1 with chromatin and growth control. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1360977.	0.3	1